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Abstract
Objective: To explore simple inexpensive non-culture based predictors of  recurrent pulmonary tuberculosis (PTB).
Setting and study population: HIV-infected and uninfected adults with the first episode of  smear positive, culture-confirmed 
pulmonary tuberculosis in a high tuberculosis burden country.
Design: A nested prospective cohort study of  participants with pulmonary tuberculosis (PTB) presenting to a hospital out-pa-
tient clinic.
Results: A total of  630 TB culture confirmed participants were followed up for eighteen months of  which 57 (9%) devel-
oped recurrent recurrent TB. On univariate analysis,4.7% low grade(1+) pre-treatment sputum smear participants developed 
recurrent tuberculosis Vs 8.8%  with high grade(3+) smears (OR=0.31,95%CI: 0.10-0.93, p=0.037).On multivariate analy-
sis:participants with extensive fibro-cavitation had a high risk of   recurrent TB Vs   minimal end of  treatment fibro-cavitation 
(18%Vs12%,OR=2.3,95%CI:1.09-4.68, p=0.03).Weight gain with HIV infection was assosciated with a high risk of  recurrent 
TB Vs weight gain with no HIV infection(18%Vs 6%,OR=6.8,95%CI:165-27.83,p=0.008) where as weight gain with a low 
pre-treatment high bacillary burden was assosciated with a low risk of  recurrent TB Vs weight gain with a high pre-treatment-
bacillary burden(6.5%Vs7.9%,OR=0.2,95%CI:0.05-0.79,p=0.02).
Conclusion: Extensive end of  treatment pulmonary fibro-cavitation, high pre-treatment bacillary burden with no weight gain 
and HIV infection could be reliable predictors of  recurrent tuberculosis.
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Introduction 
Long term, non-relapsing cure is the ultimate goal of  an-
ti-TB treatment; unfortunately recurrent disease(relapse/
re-infection) occurs on average in about two to six per-
cent of  patients with drug-susceptible TB treated with 
modern rifampicin-containing short course regimens12. 
Recurrent TB may result from recurrent disease with the 
original or new infection strain of  M. tuberculosis28.This 
may be due to several scenarios that include: poor ad-
herence, immunosuppression mainly due to HIV co-in-
fection10,13,28, Initial TB infection with a high bacillary 
burden17, drug resistant strains30, sub-optimal exposure in 
fixed dose combinations1,variation in biological response 
to TB treatment31 or exogenous re-infection with a new 
strain23. 
Clinicians have sought to identify factors associated with 
an increased risk for recurrent TB after successful initial 
treatment. This can guide them in identifying patients 
and groups where treatment might be modified or where 
post-treatment follow-up might be useful. Lack of  weight 
gain8, HIV infection13, pre-treatment greater radiographic 
involvement9, pre-treatment high bacillary burden17 ,post 
treatment residual fibro-cavitation9, sub-optimal exposure 
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in fixed dose combinations1, cavitary disease on chest ra-
diograph& a positive sputum culture after completing the 
first two months of  anti-TB treatment have been associ-
ated with recurrent tuberculosis.  
Sputum culture is costly and less affordable in many high 
TB burden settings26. Genexpert is as well costly and less 
specific in diagnosis of  recurrent TB26,27. There is a pro-
grammatic intuitive need to identify simple, robust, inex-
pensive, convenient, non culture (non-molecular) based 
tools that rely on readily available assessments at the point 
of  care to identify patients at risk for recurrent TB. Most 
TB suspects have a chest radiograph31 and sputum smear 
done during evaluation33. Patients with newly diagnosed 
TB are offered HIV testing by most programmes32 and 
even peripheral TB units have a weighing balance to mea-
sure body weight for anti-TB drug dosing. Sputum smear 
microscopy is a commonly used TB diagnostic tool even 
in resource constrained settings33. To our knowledge, 
no previous study has ever  come up with a predictive 
non-culture based tool for recurrent TB from the list of  
previously identified risk factors. In this prospective co-
hort study, we examined whether one or any  combina-
tion of  weight gain, sputum smear grade, pre-treatment 
cavitation, end of  treatment residual fibro-cavitation, ra-
diographic extent of  TB disease and HIV co-infection 
could form a non-culture based a predictive tool to iden-
tify patients at risk for recurrent TB in the initial eighteen 
months post-treatment in a well-followed up treatment 
cohort in Uganda, a nation with a high burden of  TB. 
Methods
Study population and setting
The participants included in this prospective cohort 
study were systematically selected from two parent stud-
ies. The parent studies recruited participants from sev-
eral health units within a radius of  30 kilometers from 
the research Site in Kampala. This analysis included 
data from HIV-infected and -uninfected adults over 18 
years-old with the first episode of    smear positive, cul-
ture-confirmed, drug-susceptible pulmonary TB, treated 
in  the Kawempe study(DMID protocol number:01-005)
conducted from April 2002 to July2012 and the EDCTP 
TB diagnostics study(EDCTP - IP_09_32040_011)con-
ducted from March 2010 through March 2013.Both stud-
ies were conducted at a large out-patient TB clinic within 
Mulago Hospital, a national tertiary referral hospital in 
Kampala,Uganda . All patients were treated with self-ad-
ministered, standard short course therapy (2 months of  
daily INH, rifampicin, ethambutol and pyrazinamide fol-
lowed by daily treatment with Isoniazid and rifampicin 
for 4 months). The TB drugs were dispensed as single 
drugs.1 The Kawempe study  enrolled TB index cases 
and followed up their household contacts .The Kawempe 
study embedded a mixture of  cohort and cross sectional 
designs. A  Kawempe community resident was defined 
as one who should have resided in the Kawempe area 
for at least three months. The Kawempe study excluded 
participants with recurrent TB and those who had taken 
more than 5 doses of  anti-TB drugs for that episode of  
TB at the time of  enrolment.Participants were followed 
up for eighteen months post TB treatment. A team of  
home health visitors ensured routine weekly field visits, 
phone calls and continued counseling of  the participants 
to mitigate loss to follow up. The EDCTP TB diagnostics 
study was a prospective cohort study that evaluated TB 
cytokine signatures in blood, sputum and urine as mark-
ers of  active TB infection in relation to sputum culture. It 
enrolled both controls and active TB cases, first episode 
of  TB and excluded those who had taken more than 5 
doses of  anti-TB drugs.. All culture confirmed TB cas-
es from both parent studies were systematically selected 
and screened for this analysis. Data was extracted using a 
tested and validated questionnaire by two staffs who were 
blinded to the study objective.
Procedures
HIV infection was defined as having a positive result on 
three approved, licensed rapid HIV testing kits in a vali-
dated HIV testing algorithm.Each participant had a pos-
terior-anterior chest radiograph taken pre-treatment, end 
of  treatment and at the time of  suspected TB recurrence.
The radiographic severity of  TB disease was assessed 
as minimal, moderate or far advanced disease using the 
scheme of  the US National TB and Respiratory Disease 
Association16. Body weight was measured at baseline and 
at each follow up visit using a calibrated beam balance 
(Detecto model). Sputum smear and culture were done 
monthly during the treatment phase, every 6 months 
during follow up and at the time of  suspected recurrent 
TB. Sputum smears were done using fluorescent auramine 
staining. Smear grading was by the World Health Organi-
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zation scale20. Sputum culture was on Lowenstein-Jensen 
slants. Mycobacterium tuberculosis speciation was by poly-
merase chain reaction (PCR)24. Initial isolates had drug 
susceptibility testing done for INH, rifampicin, ethambu-
tol, pyrazinamide and streptomycin. 
All participants with suspected recurrent TB were evalu-
ated by clinical examination, chest radiography, multiple 
sputum smears and cultures. Recurrent TB was defined 
as culture confirmed TB during 18 months of  follow up 
in participants who were microbiologically confirmed 
cured at the end of  the initial six months of  TB treat-
ment. Weight gain was defined as gaining at least 5% of  
the pre-treatment body weight by the end of  the first two 
months of  anti-TB treatment8. 
Treatment adherence was monitored by urine INH me-
tabolite testing in addition to participant interview at 
each scheduled visit and review of  attendance records. 
Defaulters were traced by home health visitors. All par-
ticipants were followed up for 18 months after TB treat-
ment.  Both parent studies were approved by institutional 
review boards of  the Joint Clinical Research Centre, the 
National AIDS Research Committee and the Ugandan 
National Council for Science and Technology. All partic-
ipants gave written informed consent for participation in 
the parent studies. 
Statistical analysis
Categorical data was analyzed using the chi-square. For 
weight gain, changes from baseline by month 2 were as-
sessed using paired z-tests. Logistic regression was used 
in determining the association between weight gain, HIV 
status, radiographic extent of  disease, sputum smear 
grade, end of  treatment fibro-cavitation and the likeli-
hood of  TB recurrence.Stepwise selection method of  
predictor variables(weight gain,HIV status,chest x-ray ex-
tent of  disease,fibro-cavitation and bacillary burden) was 
used for inclusion in the logistic model. All tests were 
two-sided. The odds ratio plus the corresponding 95% 
confidence interval and p-value were the effect measure. 
A confidence interval excluding the null value of  1 and 
a p-value<0.05 were considered statistically significant. 
All statistical analyses were done using Stata (Version 12, 
STATA, USA).
Results
A total of  1150 ( figure 1 ) were screened and 690 bac-
teriologically confirmed PTB study participants were en-
rolled in the two parent studies between April 2001 and 
July 2012 of  which 60 were excluded from this analysis 
since they were not followed up after completing treat-
ment. Of  the 630 followed up, 57 (9%) developed re-
current TB, 136(22%) were HIV infected, 311(49%) had 
far advanced disease on chest radiograph & 363(58%) 
had pulmonary cavitation. Majority 331(52%) were fe-
male & recurrent TB cases were older (mean age=30 yrs, 
SD=10.8 :) Vs the non- recurrent (NR) group (mean age 
28.6yrs: SD=10.2).106(17%) had a low grade pretreat-
ment smear & 160(25%) had a high grade smear. Major-
ity 510(81%) had urine INH testing to confirm TB treat-
ment adherence.
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Figure 1:  Study profile 1 
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Table 1: Univariate analysis 1 
































HIV positive 12 124 136 0.92 
Baseline cavities 38 325 363 0.15 
Chest x-ray 


















































On univariate analysis(table 1),4.7% of  the low grade 
smear  participants developed recurrent TB Vs 8.8% 
with a high grade smear  (OR=0.31, 95%CI: 0.10-0.93, 
p=0.037). Weight gain and HIV infection did not inde-
pendently influence the rate of  recurrent TB on univari-
ate analysis.On multivariate analysis:table 2; 
 1 
Table 2: Multivariate analysis 2 
Variable Recurrent Non-Recurrent Total  95%CI P-value 
Weight gain<5%,HIV+ 5 80 85    0.18-1.3 0.14 
Weight gain≥5%,HIV- 11 165 176  1.7-27.8 0.008 
Weightgain≥5%,moderate 
disease 
05 44 49 0.14-20.66 0.68 
Weightgain≥5%,advanced 
disease 
12 122 1340.15-16.84 0.69 
HIV-,moderate disease 15 159 1740.6-6.8 0.23 
HIV-,advanced disease 39 268 307    0.46-26.9 0.20 
Smear 1+, Weight gain≥5% 3 70 730.05-0.79 0.02 
 3 
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weight gain with a low grade smear was associated with 
an even lower  risk of  recurrent TB Vs weight gain with 
a high pre-treatment bacillary burden(OR=0.2,95%CI: 
0.05-0.79,P=0.02):. Weight gain with HIV infection was 
associated with a high risk of  recurrent TB Vs weight gain 
with no HIV infection (18% Vs 6%, OR=6.8,95%CI:165-
27.83,p=0.008.About 18% of  those with extensive fi-
bro-cavitary sequellae at the end of  TB treatment devel-
oped recurrent TB Vs 12% with minimal fibro-cavitary 
sequellae (OR=2.3, 95%CI: 1.09-4.68, P=0.03): table 3.
Table 3: Radiographic extent of disease at month 6(fibro-cavitation) 1 
Variable Recurrent Non-Recurrent Total  95%CI P-value 
Minimal 16 123 139    -------- ----- 
Moderate 15 108 123    0.7-2.8 0.33 
Advanced 13 58 71 1.1-4.7 0.03 
 2 
Discussion
In this analysis,we report a 2 fold reduction in the risk 
of  recurrent TB among participants with low grade com-
pared to high grade pre-treatment smears (4.7%Vs8.8%) 
and inversely an increase in the risk of  recurrent TB 
among participants with extensive end of  treatment fi-
bro-cavitary sequellae   compared to those with minimal 
fibro-cavitary sequellae (18%Vs12%). Rupka Singla et al 
2007 and panJab et al 2007 showed that high pre-treat-
ment bacillary burden and residual cavitation by the end 
of  TB treatment  increases the risk for recurrent TB. Lu-
zze et al 2013 showed that extensive end of  treatment 
fibrosis and cavitation was associated with recurrent TB. 
Therefore our findings are similar to what has been re-
ported in previous studies9,17,28. Participants with a low 
grade pretreatment smear and weight gain had an even 
lower risk of  recurrent TB but weight gain alone did not 
independently influence the risk of  recurrence8. We how-
ever observed a high proportion of  failed weight gain in 
the recurrent TB group compared to their non-recurrent 
counter parts (67% Vs 59%) but this was not statistically 
significant although Khan et al 20068 showed that fail-
ure to gain ≥ 5% of  baseline body weight by the end of  
the intensive phase of  TB treatment was associated with 
an increased risk for TB recurrence. Our study found no 
statistically significant difference on univariate analysis al-
though there was a higher proportion of  failed weight 
gain in the recurrent Vs the non-recurrent group. We also 
observed an increased risk of  recurrent TB among the 
HIV infected with weight gain Vs HIV uninfected with 
weight gain. Previous studies have shown increased rates 
of  TB recurrence among HIV-TB patients10, this was  the 
case with our study results too.  We  noted a higher pro-
portion of  recurrent TB (9%) in this population contrary 
to previously existing scientific data12 however,our results 
are in line with the findings of  one previous study in the 
same population28. The high proportion of  recurrent 
TB could be attributed to patients presenting late with 
advanced PTB9 as evidenced in this analysis where the 
majority( 49%) of  the participants had radiographically 
far advanced disease. This is in agreement with Panjab et 
al 2007 findings of  greater radiographic involvement be-
ing a risk factor for recurrent TB Urine INH metabolite 
testing was not done in 19% of  the cases in which case 
non-adherence could have confounded recurrent PTB29. 
We also noted that about 54% of  the cases presented 
with a high pre-treatment bacillary burden which could 
partially explain the  high proportions of  recurrent TB in 
this population17.
The strength of  our study is that it involved an eighteen 
month follow-up of  a large cohort of  confirmed TB pa-
tients and monthly assessment of  adherence by urinary 
INH metabolite testing during treatment. Our study had 
several limitations (i) the urine INH metabolite testing 
was only possible in 81% of  the cases included in this 
analysis.  (ii)DNA finger printing was not done to distin-
guish recurrent TB due to relapse from exogenous rein-
fection with a different strain28. 
Recommendation
Previous studies have listed several factors assosciated 
with TB disease recurrence but no predictive tool has 
been assembled out of  this literature to influence man-
agement of  recurrent TB. We recommend that clinicians 
should put into perspective the possibility of  prolong-
ing treatment and close patient monitoring for TB pa-
African Health Sciences Vol 19 Issue 2, June, 20192096
tientswho :(i) present with a high pre-treatment bacillary 
burden (3+) and failure to gain at least 5% of  baseline 
body weight by the end of  the intensive phase of  TB 
treatment. (ii)Are HIV positive.(iii) have extensive end of  
treatment fibrosis and residual cavitation on chest x-ray 
(grade 3).
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